Kura Oncology (KURA) Prices 8.11M Share Common Offering at $37/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up about 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Kura Oncology (KURA) to Offer $200M in Common Stock
December 7, 2020 4:01 PM ESTKura Oncology, Inc. (Nasdaq: KURA) announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $200,000,000 of shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to... More
Pre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...)
December 7, 2020 9:26 AM ESTToday's Pre-Open Stock Movers
Eastman Kodak Company (NYSE: KODK) 72% HIGHER; news that federal regulators found no wrongdoing in getting a loan from the government.
Kura Oncology, Inc. (Nasdaq: KURA) 16.9% HIGHER; announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial of the Companys oral, potent and selective menin inhibitor, KO-539, including single-agent activity in genetically defined subgroups of patients with relapsed or refractory acute myeloid leukemia (AML).
Matinas BioPharma Holdings, Inc. (NYSE:... More
Kura Oncology (KURA) PT Raised to $45 at H.C. Wainwright After ASH Presentation
December 7, 2020 7:12 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Kura Oncology (NASDAQ: KURA) to $45.00 (from $40.00) after an oral presentation at ASH offered the first important look at preliminary Phase 1/2a data with KO-539 in r/r AML patients from the ongoing KOMET... More
Kura Oncology (KURA) PT Raised to $47 at Barclays
December 7, 2020 4:47 AM ESTBarclays analyst Peter Lawson raised the price target on Kura Oncology (NASDAQ: KURA) to $47.00 (from $40.00) while maintaining a Overweight rating.... More

